The Exchange has sought clarification from Wanbury Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1.Consolidated Financial Results not submitted -1. Consolidated Financial Results not submitted The response of the Company is awaited.
WANBURY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.8 pts less than Nifty Microcap 250 and 1.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The National Stock Exchange has asked Wanbury Limited to explain why it failed to submit its Consolidated Financial Results for the quarter ended September 30, 2025, as required under Regulation 33 of SEBI's Listing Obligations and Disclosure Requirements. Filing consolidated results alongside standalone results is a mandatory quarterly compliance for listed companies. The company has not yet responded to the exchange's query. Until Wanbury clarifies or submits the results, the matter remains open with the exchange.
This is a compliance lapse that may attract regulatory action or penalties from the exchanges and SEBI if not resolved quickly. For shareholders, the delayed disclosure of consolidated numbers reduces transparency into the group's full financial health, and could weigh negatively on the stock in the short term until the results are filed.